Every new portfolio company at Paramount BioSciences is built around intriguing science and commercial potential, as well as a first-class management team.
While venture capital and private equity firms tend to be investment-oriented, Paramount BioSciences’ bias is corporate formation. It builds companies from the ground up, using its own capital and eventually funds raised from diverse private and institutional investors through its affiliate, Paramount BioCapital, Inc., a FINRA registered broker-dealer. As much as any other feature, it is Paramount BioSciences’ financial and business experience that makes it so attractive to licensors and CEOs. With Paramount BioSciences handling accounting, financial, legal, and market analytical functions, managers of its portfolio companies are empowered to do what they are trained to do: drive drug candidates through clinical trials and create value for shareholders, licensors, and patients.